The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Helmut Drexler - One of the best experts on this subject based on the ideXlab platform.
-
growth differentiation factor 15 for risk stratification and selection of an invasive Treatment Strategy in non st elevation acute coronary syndrome
Circulation, 2007Co-Authors: Kai C Wollert, Tibor Kempf, Bo Lagerqvist, Bertil Lindahl, Sylvia Olofsson, Tim Allhoff, Timo Peter, Agneta Siegbahn, Per Venge, Helmut DrexlerAbstract:Background— An invasive Treatment Strategy improves outcome in patients with non–ST-elevation acute coronary syndrome at moderate to high risk. We hypothesized that the circulating level of growth ...
-
growth differentiation factor 15 for risk stratification and selection of an invasive Treatment Strategy in non st elevation acute coronary syndrome
Circulation, 2007Co-Authors: Kai C Wollert, Tibor Kempf, Bo Lagerqvist, Bertil Lindahl, Sylvia Olofsson, Tim Allhoff, Timo Peter, Agneta Siegbahn, Per Venge, Helmut DrexlerAbstract:Background— An invasive Treatment Strategy improves outcome in patients with non–ST-elevation acute coronary syndrome at moderate to high risk. We hypothesized that the circulating level of growth differentiation factor 15 (GDF-15) may improve risk stratification. Methods and Results— The Fast Revascularization during InStability in Coronary artery disease II (FRISC-II) trial randomized patients with non–ST-elevation acute coronary syndrome to an invasive or conservative Strategy with a follow-up for 2 years. GDF-15 and other biomarkers were determined on admission in 2079 patients. GDF-15 was moderately elevated (between 1200 and 1800 ng/L) in 770 patients (37.0%), and highly elevated (>1800 ng/L) in 493 patients (23.7%). Elevated levels of GDF-15 independently predicted the risk of the composite end point of death or recurrent myocardial infarction in the conservative group (P=0.016) but not in the invasive group. A significant interaction existed between the GDF-15 level on admission and the effect of ...
Kai C Wollert - One of the best experts on this subject based on the ideXlab platform.
-
growth differentiation factor 15 for risk stratification and selection of an invasive Treatment Strategy in non st elevation acute coronary syndrome
Circulation, 2007Co-Authors: Kai C Wollert, Tibor Kempf, Bo Lagerqvist, Bertil Lindahl, Sylvia Olofsson, Tim Allhoff, Timo Peter, Agneta Siegbahn, Per Venge, Helmut DrexlerAbstract:Background— An invasive Treatment Strategy improves outcome in patients with non–ST-elevation acute coronary syndrome at moderate to high risk. We hypothesized that the circulating level of growth ...
-
growth differentiation factor 15 for risk stratification and selection of an invasive Treatment Strategy in non st elevation acute coronary syndrome
Circulation, 2007Co-Authors: Kai C Wollert, Tibor Kempf, Bo Lagerqvist, Bertil Lindahl, Sylvia Olofsson, Tim Allhoff, Timo Peter, Agneta Siegbahn, Per Venge, Helmut DrexlerAbstract:Background— An invasive Treatment Strategy improves outcome in patients with non–ST-elevation acute coronary syndrome at moderate to high risk. We hypothesized that the circulating level of growth differentiation factor 15 (GDF-15) may improve risk stratification. Methods and Results— The Fast Revascularization during InStability in Coronary artery disease II (FRISC-II) trial randomized patients with non–ST-elevation acute coronary syndrome to an invasive or conservative Strategy with a follow-up for 2 years. GDF-15 and other biomarkers were determined on admission in 2079 patients. GDF-15 was moderately elevated (between 1200 and 1800 ng/L) in 770 patients (37.0%), and highly elevated (>1800 ng/L) in 493 patients (23.7%). Elevated levels of GDF-15 independently predicted the risk of the composite end point of death or recurrent myocardial infarction in the conservative group (P=0.016) but not in the invasive group. A significant interaction existed between the GDF-15 level on admission and the effect of ...
Per Venge - One of the best experts on this subject based on the ideXlab platform.
-
growth differentiation factor 15 for risk stratification and selection of an invasive Treatment Strategy in non st elevation acute coronary syndrome
Circulation, 2007Co-Authors: Kai C Wollert, Tibor Kempf, Bo Lagerqvist, Bertil Lindahl, Sylvia Olofsson, Tim Allhoff, Timo Peter, Agneta Siegbahn, Per Venge, Helmut DrexlerAbstract:Background— An invasive Treatment Strategy improves outcome in patients with non–ST-elevation acute coronary syndrome at moderate to high risk. We hypothesized that the circulating level of growth ...
-
growth differentiation factor 15 for risk stratification and selection of an invasive Treatment Strategy in non st elevation acute coronary syndrome
Circulation, 2007Co-Authors: Kai C Wollert, Tibor Kempf, Bo Lagerqvist, Bertil Lindahl, Sylvia Olofsson, Tim Allhoff, Timo Peter, Agneta Siegbahn, Per Venge, Helmut DrexlerAbstract:Background— An invasive Treatment Strategy improves outcome in patients with non–ST-elevation acute coronary syndrome at moderate to high risk. We hypothesized that the circulating level of growth differentiation factor 15 (GDF-15) may improve risk stratification. Methods and Results— The Fast Revascularization during InStability in Coronary artery disease II (FRISC-II) trial randomized patients with non–ST-elevation acute coronary syndrome to an invasive or conservative Strategy with a follow-up for 2 years. GDF-15 and other biomarkers were determined on admission in 2079 patients. GDF-15 was moderately elevated (between 1200 and 1800 ng/L) in 770 patients (37.0%), and highly elevated (>1800 ng/L) in 493 patients (23.7%). Elevated levels of GDF-15 independently predicted the risk of the composite end point of death or recurrent myocardial infarction in the conservative group (P=0.016) but not in the invasive group. A significant interaction existed between the GDF-15 level on admission and the effect of ...
-
frisc score for selection of patients for an early invasive Treatment Strategy in unstable coronary artery disease
Heart, 2005Co-Authors: B Lagerqvist, Agneta Siegbahn, Per Venge, Erik Diderholm, B Lindahl, Steen Husted, F Kontny, Elisabeth Stahle, Eva Swahn, Lars WallentinAbstract:OBJECTIVE: To develop a scoring system for risk stratification and evaluation of the effect of an early invasive Strategy for Treatment of unstable coronary artery disease (CAD). DESIGN: Retrospective analysis of a randomised study (FRISC II; fast revascularisation in instability in coronary disease). SETTING: 58 Scandinavian hospitals. PATIENTS: 2457 patients with unstable CAD from the FRISC II study. MAIN OUTCOME MEASURES: One year rates of mortality and death/myocardial infarction (MI). METHODS: Patients were randomly assigned to an early invasive or a non-invasive Strategy. From the non-invasive cohort independent variables of death or death/MI were identified. RESULTS: Seven factors, age > 70 years, male sex, diabetes, previous MI, ST depression, and increased concentrations of troponins and markers of inflammation (interleukin 6 or C reactive protein), were associated with an independent increased risk for death or death/MI. In patients with > or = 5 of these factors the invasive Strategy reduced mortality from 15.4% (20 of 130) to 5.2% (7 of 134) (risk ratio (RR) 0.34, 95% confidence interval (CI) 0.15 to 0.78, p = 0.006). Death/MI was also reduced in patients with 3-4 factors from 15.7% (80 of 511) to 10.8% (58 of 538) (RR 0.69, 95% CI 0.50 to 0.94, p = 0.02). Neither death nor death/MI was reduced in patients with 0-2 risk factors. CONCLUSION: In unstable CAD, this scoring system based on factors independently associated with an adverse outcome can be used shortly after admission to the hospital for risk stratification and for selection of patients to an early invasive Treatment Strategy.
Agneta Siegbahn - One of the best experts on this subject based on the ideXlab platform.
-
growth differentiation factor 15 for risk stratification and selection of an invasive Treatment Strategy in non st elevation acute coronary syndrome
Circulation, 2007Co-Authors: Kai C Wollert, Tibor Kempf, Bo Lagerqvist, Bertil Lindahl, Sylvia Olofsson, Tim Allhoff, Timo Peter, Agneta Siegbahn, Per Venge, Helmut DrexlerAbstract:Background— An invasive Treatment Strategy improves outcome in patients with non–ST-elevation acute coronary syndrome at moderate to high risk. We hypothesized that the circulating level of growth ...
-
growth differentiation factor 15 for risk stratification and selection of an invasive Treatment Strategy in non st elevation acute coronary syndrome
Circulation, 2007Co-Authors: Kai C Wollert, Tibor Kempf, Bo Lagerqvist, Bertil Lindahl, Sylvia Olofsson, Tim Allhoff, Timo Peter, Agneta Siegbahn, Per Venge, Helmut DrexlerAbstract:Background— An invasive Treatment Strategy improves outcome in patients with non–ST-elevation acute coronary syndrome at moderate to high risk. We hypothesized that the circulating level of growth differentiation factor 15 (GDF-15) may improve risk stratification. Methods and Results— The Fast Revascularization during InStability in Coronary artery disease II (FRISC-II) trial randomized patients with non–ST-elevation acute coronary syndrome to an invasive or conservative Strategy with a follow-up for 2 years. GDF-15 and other biomarkers were determined on admission in 2079 patients. GDF-15 was moderately elevated (between 1200 and 1800 ng/L) in 770 patients (37.0%), and highly elevated (>1800 ng/L) in 493 patients (23.7%). Elevated levels of GDF-15 independently predicted the risk of the composite end point of death or recurrent myocardial infarction in the conservative group (P=0.016) but not in the invasive group. A significant interaction existed between the GDF-15 level on admission and the effect of ...
-
frisc score for selection of patients for an early invasive Treatment Strategy in unstable coronary artery disease
Heart, 2005Co-Authors: B Lagerqvist, Agneta Siegbahn, Per Venge, Erik Diderholm, B Lindahl, Steen Husted, F Kontny, Elisabeth Stahle, Eva Swahn, Lars WallentinAbstract:OBJECTIVE: To develop a scoring system for risk stratification and evaluation of the effect of an early invasive Strategy for Treatment of unstable coronary artery disease (CAD). DESIGN: Retrospective analysis of a randomised study (FRISC II; fast revascularisation in instability in coronary disease). SETTING: 58 Scandinavian hospitals. PATIENTS: 2457 patients with unstable CAD from the FRISC II study. MAIN OUTCOME MEASURES: One year rates of mortality and death/myocardial infarction (MI). METHODS: Patients were randomly assigned to an early invasive or a non-invasive Strategy. From the non-invasive cohort independent variables of death or death/MI were identified. RESULTS: Seven factors, age > 70 years, male sex, diabetes, previous MI, ST depression, and increased concentrations of troponins and markers of inflammation (interleukin 6 or C reactive protein), were associated with an independent increased risk for death or death/MI. In patients with > or = 5 of these factors the invasive Strategy reduced mortality from 15.4% (20 of 130) to 5.2% (7 of 134) (risk ratio (RR) 0.34, 95% confidence interval (CI) 0.15 to 0.78, p = 0.006). Death/MI was also reduced in patients with 3-4 factors from 15.7% (80 of 511) to 10.8% (58 of 538) (RR 0.69, 95% CI 0.50 to 0.94, p = 0.02). Neither death nor death/MI was reduced in patients with 0-2 risk factors. CONCLUSION: In unstable CAD, this scoring system based on factors independently associated with an adverse outcome can be used shortly after admission to the hospital for risk stratification and for selection of patients to an early invasive Treatment Strategy.
Tibor Kempf - One of the best experts on this subject based on the ideXlab platform.
-
growth differentiation factor 15 for risk stratification and selection of an invasive Treatment Strategy in non st elevation acute coronary syndrome
Circulation, 2007Co-Authors: Kai C Wollert, Tibor Kempf, Bo Lagerqvist, Bertil Lindahl, Sylvia Olofsson, Tim Allhoff, Timo Peter, Agneta Siegbahn, Per Venge, Helmut DrexlerAbstract:Background— An invasive Treatment Strategy improves outcome in patients with non–ST-elevation acute coronary syndrome at moderate to high risk. We hypothesized that the circulating level of growth ...
-
growth differentiation factor 15 for risk stratification and selection of an invasive Treatment Strategy in non st elevation acute coronary syndrome
Circulation, 2007Co-Authors: Kai C Wollert, Tibor Kempf, Bo Lagerqvist, Bertil Lindahl, Sylvia Olofsson, Tim Allhoff, Timo Peter, Agneta Siegbahn, Per Venge, Helmut DrexlerAbstract:Background— An invasive Treatment Strategy improves outcome in patients with non–ST-elevation acute coronary syndrome at moderate to high risk. We hypothesized that the circulating level of growth differentiation factor 15 (GDF-15) may improve risk stratification. Methods and Results— The Fast Revascularization during InStability in Coronary artery disease II (FRISC-II) trial randomized patients with non–ST-elevation acute coronary syndrome to an invasive or conservative Strategy with a follow-up for 2 years. GDF-15 and other biomarkers were determined on admission in 2079 patients. GDF-15 was moderately elevated (between 1200 and 1800 ng/L) in 770 patients (37.0%), and highly elevated (>1800 ng/L) in 493 patients (23.7%). Elevated levels of GDF-15 independently predicted the risk of the composite end point of death or recurrent myocardial infarction in the conservative group (P=0.016) but not in the invasive group. A significant interaction existed between the GDF-15 level on admission and the effect of ...
